Vedolizumab in the perioperative management of inflammatory bowel disease

Amy L. Lightner, Edward V. Loftus, Nicholas P. McKenna, Laura E. Raffals

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Background: The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. Objective: To determine the risk of vedolizumab on postoperative complications. Methods: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn’s disease or ulcerative colitis individually, and those which included pediatric patients alone. Results: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn’s disease literature. Conclusion: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn’s disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.

Original languageEnglish (US)
Pages (from-to)1317-1322
Number of pages6
JournalCurrent drug targets
Issue number13
StatePublished - 2019


  • Crohn’s disease
  • Inflammatory bowel disease
  • Intra-abdominal sepsis
  • Postoperative infectious complications
  • Surgical intervention
  • Ulcerative colitis
  • Vedolizumab

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Vedolizumab in the perioperative management of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this